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Borderline epithelial ovarian tumours (BOT) were described 70
years ago as semimalignant tumours (Taylor, 1929), although
diagnostic criteria were not refined until the early 1970s
(International Federation of Gynaecology and Obstetrics, 1971;
Serov et al, 1973). The diagnosis is made on histological criteria
that there is epithelial proliferation, multilayering and atypical
cytological features but an absence of destructive stromal invasion
(Scully et al, 1979). The majority of these tumours are of serous or
mucinous subtype, the latter being of intestinal or Müllerian type.
BOT can also be classified according to the presence of extra-
ovarian, peritoneal disease. While peritoneal disease (implants)
may be seedlings (superficial metastases) in the pelvic peri-
toneum, many of them represent foci of peritoneal metaplasia. The
epithelium in these latter foci may be benign (endosalpingiosis)
but may show the same characteristics as that in the ovarian
neoplasm (Gershenson et al, 1990; Bell et al, 1991; Kurman and
Trimble, 1993; Michael et al, 1993). Serous implants may also be
subdivided into non-invasive (desmoplastic and epithelial) and
invasive types (Michael and Roth, 1986; Bell et al, 1988); the
latter can be treated as an invasive malignant tumour (Bell et al,
1988). Furthermore serous borderline tumour with microinvasion
(individual or clusters of cells) (Tavassoli et al, 1988; Bell and
Scully, 1990) has also been described. Mucinous tumours of
intestinal type can be associated with pseudomyxoma peritoneii
and there is evidence that some of these tumours may be metas-
tases from a primary adenoma or adenocarcinoma of the vermi-
form appendix (Hinson and Ambrose, 1998).
The survival of patients with BOT is good. In a review of 953
patients that excluded those with invasive implants the survival of
patients with stage I disease and stage III disease was 99% and
92% respectively at a median of 7 years follow-up (Kurman and
Trimble, 1993). However, other reports have shown that the
disease can follow an indolently progressive course with a 30%
relapse rate over 7 years after diagnosis (Gershenson et al, 1998).
Nevertheless, these survival statistics are significantly better than
those for ovarian cancer.
The principal modality of treatment for BOT is surgery, whereas
ovarian cancer is largely treated with surgery and chemotherapy.
Thus the incorrect ascription of a diagnosis of ovarian cancer to a
patient who has BOT will result in the patient receiving
chemotherapy and incorrect information concerning long-term
survival. In addition a correct diagnosis of BOT in a younger
woman would allow the preservation of fertility. This study reports
the results of expert histopathological review of cases that were
finally managed as having BOT.
MATERIALS AND METHODS
The pathology of all cases of ovarian neoplasms referred to the
Department of Medical Oncology (Christie Hospital National
Health Trust) is reviewed by pathologists with a special interest in
gynaecological oncology (Serov et al, 1973). The patients who
were managed as having BOT between 1988 and 1997 were
included in this study. Prospective demographic information was
gathered and the FIGO stage was determined through a summation
of pathological, clinical and radiological findings (FIGO, 1971).
RESULTS
Sixty-four patients with a diagnosis of BOT, following pathology
review, were identified for the study. Their demographic details
are shown in Table 1. The median age was 48 years (range 23–88
years) with a 5-year survival of 79% for all stages. None of the
patients had a history of another cancer. Interestingly, 24 patients
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breast, bowel, prostate and other cancers).
Examination of the original pathology report (issued before
specialist pathology review) showed that in 27 cases (42.2%) the
original diagnosis was of an invasive carcinoma of the ovary. In 17
cases these were described as well differentiated tumours and in
two cases as moderately differentiated tumours. The differentia-
tion status was not described in the remaining eight cases. Twenty-
three of the cases originally described as carcinomas were not
associated with peritoneal involvement; the remaining four were
associated with non-invasive implants. Of the cases originally
described as carcinomas, 11 were FIGO stage I tumours (three
stage Ia; one stage Ib; seven stage Ic), five were stage II tumours
and ten stage III tumours (Table 1).
Ten of the 64 patients (including five originally described as carci-
noma) with borderline tumours received chemotherapy. One of the
patients that received chemotherapy had stage II disease and the rest
had stage III disease. Of the nine patients that could be assessed for
response, there was one complete response and one partial response.
Five patients had a second laparotomy after chemotherapy.
The median follow-up for these patients was 3.1 years (range 40
days to 12.1 years). There were seven disease-related deaths and
one intercurrent death; 46 patients remain alive and disease-free;
nine are alive with stable disease; one is alive with recurrent
disease. Of the patients who received chemotherapy, four were
disease-free at follow-up, three had stable disease, one was alive
with recurrent disease, two had died of disease. In two cases there
was histopathologically confirmed malignant transformation to
invasive carcinoma (one death). The 5-year event-free survival
(death, progression or recurrence) for stage I and II patients versus
stage III was 87% and 53% respectively (P = 0.01). However, a
comparison between the event-free survival for the group initially
diagnosed with carcinomas and that of the group where the diag-
nosis was not changed, revealed no difference between the groups
with a 70% 6-year event-free survival (P = 0.5) (Figure 1).
DISCUSSION
This is a study of 64 patients with a diagnosis of borderline ovarian
cancer managed at a specialist centre. The patients had been
referred from other hospitals in the region and this accounts for 
the atypical distribution of FIGO stage in patients with BOT.
Although only a minority of patients received chemotherapy, the
prognosis for these tumours is good, with a 79% 5-year survival
from diagnosis. However, patients with FIGO stage III disease had
a worse prognosis. Interestingly, nearly 40% of the patients gave a
family history of another epithelial cancer, a finding that has not
been reported previously in studies of patients with BOT.
The most striking feature of this study was the finding that in 27
cases (42.2%) the original diagnosis was of invasive ovarian
carcinoma prior to specialist gynaecological oncology pathology
review. However, of the 27 cases where the diagnosis was revised,
only four were FIGO stage Ia–Ib. The remaining cases were 
FIGO stage Ic–III (one unknown) and would have received
chemotherapy had the diagnosis not been changed. There was no
difference in event-free survival between the group that had a
changed histopathological diagnosis and those with an unchanged
diagnosis (P = 0.5). This high frequency of change in diagnosis
may be due to the referral bias that led to a high proportion of
advanced-stage patients in the series.
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Table 1 Clinicopathological characteristics of patients
Characteristic Total OVCA BOT
n = 64 (%/64) n = 27 (%/27) n = 37 (%/37)
Histopathology
Mucinous 33 (51.6) 13 (48.1) 20 (54.1)
Serous 25 (39.0) 11 (40.7) 14 (37.8)
Mixed 4 (6.2) 1 (3.7) 3 (8.1)
Endometrioid 1 (1.6) 1 (3.7) 0 (0.0)
Other 1 (1.6) 1 (3.7) 0 (0.0)
Endosalpingiosis 6 (9.4) 2 (7.4) 4 (10.8)
Non-invasive implants 4 (6.3) 4 (14.8) 0 (0.0)
Invasive implants 3 (4.7) 0 (0.0) 3 (8.1)
Pseudomyxoma peritoneii 8 (12.5) 5 (18.5) 3 (8.1)
FIGO stage
Ia 21 (32.8) 3 (11.1) 18 (48.6)
Ib 4 (6.3) 1 (3.7) 3 (8.1)
Ic 13 (20.3) 7 (25.9) 6 (16.2)
II 7 (10.9) 5 (18.5) 2 (5.4)
III 18 (28.1) 10 (37.0) 8 (21.6)
Unknown 1 (1.6) 1 (3.7) 0 (0.0)
Residual disease
Nil 38 (59.4) 9 (33.3) 29 (78.4)
Minimal (0–2 cm) 7 (10.9) 5 (18.5) 2 (5.4)
Bulk (> 2 cm) 12 (18.8) 8 (29.6) 4 (10.8)
Uncertain 7 (10.9) 5 (18.5) 2 (5.4)
Performance status (KP)
100% 6 (9.3) 0 (0.0) 6 (16.2)
90% 26 (39.1) 10 (37.0) 16 (43.2)
80% 15 (23.4) 7 (25.9) 8 (21.6)
40–70% 3 (4.7) 1 (3.7) 2 (5.4)
Unknown 14 (21.9) 9 (33.3) 5 (13.5)
Disease status at follow-up
Disease free 46 (71.9) 16 (59.3) 30 (81.1)
Stable disease 9 (14.1) 5 (18.5) 4 (10.8)
Recurrent disease 1 (1.6) 1 (3.7) 0 (0.0)
Dead disease 7 (10.9) 5 (18.5) 2 (5.4)
Intercurrent death 1 (1.6) 0 (0.0) 1 (2.7)
BOT: patients originally diagnosed as having borderline ovarian tumours;
OVCA: patients originally diagnosed as having invasive ovarian tumours.
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Figure 1 Comparison of event-free survival of patients (BOT: patients
originally diagnosed as having borderline ovarian tumours; OVCA: patients
originally diagnosed as having invasive ovarian tumours). Note one case in
the BOT group was missing necessary information and hence has been
omitted here762 PS Sengupta et al
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Coupled with the long event-free survival that compares with
other BOT series, the implication is that borderline tumour was the
correct designation. As chemotherapy is associated with early and
late morbidity and mortality, most patients with BOT will be
spared these toxicities and clinicians will give patients the correct
information concerning prognosis. These data support the need for
expert histopathological evaluation of ovarian tumours.
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